

Europe's Beating Cancer Plan



Diagnosis and treatment


Start date - end date 01/11/2022 - 31/10/2024

Countries

Belgium, Czech Republic, Denmark, Estonia, France, Germany, Greece, Italy, Latvia, Luxembourg, Malta, Netherlands, Poland, Portugal, Serbia, Slovenia, Spain

Overall budget EUR 7 476 270

EU contribution under EU4Health programme EUR 5 981 016



CAN.HEAL – Building the EU Cancer and Health Genomics platform


The CAN.HEAL project contributes by upscaling available innovation in personalised medicine to improve access to prevention, diagnosis and treatment for all Europeans. The goal is to bridge the gap between public health genomics and genomics for diagnosis and treatment.

Cancer development is traditionally linked to changes at genome level, and these modifications are a significant driver of cancer. Wide profiling of modifications has become a major asset for diagnosis, prognosis and therapy.

The CAN.HEAL consortium recognises the need for a comprehensive approach to prevention, diagnosis and treatment for optimal outcomes. The project aims to establish recommendations for EU health systems that improve patient access to prevention, diagnosis and treatment of cancer through **individual and personalised medicine**.

The project's clinical work focuses on applying 'next generation sequencing' technology and identifying implementation paths to extend the application of genetic profiling of patients and tumour cells.

This will enable EU Cancer Centres to:



- take advantage of national initiatives to structure omics
 such as genomics and transcriptomics to allow
 harmonised data interpretation in patient care;
- better share their data;
- take up molecular tumour profiling biomarkers that estimate cancer predisposition.

The project will also conduct further work on the application of novel insights for estimating cancer risks in healthy populations using polygenic risk score analysis as part of population-wide interventions, along with strategies for remote genetic counselling and telegenetics.

Expected project outcomes include:

- tools and procedures to integrate and align clinical and population-based interventions;
- guidelines and tools for the evaluation of value-based innovation adoption in personalised medicine;
- strategies for the implementation of telegenetics and remote genetic counselling;
- building clinical utility for cancers in pregnancy, familybased genetic testing in pediatric leukemia, and Polygenic Risk Scores (PRS) in cancer risk stratification;
- strategies for wet lab tools, Molecular Tumor Boards (MTB) and Comprehensive Genomic Profiling (CGP) for early detection, diagnosis and treatment;
- recommendations on the use of Decision Support Tools
 (DST) in cancer prevention, diagnosis and treatment;
- national capacity building of clinical and populationbased interventions;
- specific education and training for health workers in genomics and cancer care and control;
- deeper ethical and legal consents towards access to medical information;
- recommendations concerning the implementation of Polygenic Risk Scores (PRS) and liquid biopsy in cancer management.

For more info

Contact details

Marc Van den Bulcke / Els Van Valckenborgh Els.Vanvalckenborgh@ sciensano.be + 32 2 642 54 96

Project website https://canheal.eu

Social media handles

@CanHealeu



Europe's Beating Cancer Plan makes use of the whole range of Commission funding instruments with a total of \in 4 billion being earmarked for actions addressing cancer. \in 1.25 billion from the EU4Health programme is being used to support actions and initiatives outlined in the Cancer Plan.

© European Union, 2023

Reuse of this document is allowed, provided appropriate credit is given and any changes are indicated (Creative Commons Attribution 4.0 International license). For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders. All images © Gettyimages